Atea Pharmaceuticals (AVIR) will virtually host a hepatitis C virus key opinion leade panel discussion on topics related to the treatment of HCV on Wednesday, May 14, 2025 at 10:00 AM ET. Atea also announced that it plans to issue a press release and report its first quarter 2025 financial results after the market closes on Monday, May 12, 2025. Atea will not host a first quarter conference call and plans to resume the quarterly calls with the second quarter 2025 financial results. This event will include a panel of several US and ex-US physicians who are leaders in hepatology, gastroenterology, infectious diseases and HCV treatments. These experts and prescribers will discuss the current challenges encountered by patients with HCV, the results from Atea’s global Phase 2 study evaluating the regimen of bemnifosbuvir, a nucleotide analog polymerase inhibitor, and ruzasvir, an NS5A inhibitor, for the treatment of HCV, and what a new optimized HCV therapy could provide for prescribers and patients. Company management will discuss the HCV commercial market opportunity and the ongoing global Phase 3 clinical development.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AVIR:
- Atea Pharmaceuticals announces results from phase 2 study of bemnifosbuvir
- Atea Pharmaceuticals Announces Board Changes and Share Buyback
- Atea Pharmaceuticals board authorizes $25M share repurchase program
- Atea Pharmaceuticals says strategic alternatives process ‘ongoing’
- Atea Pharmaceuticals appoints Howard Berman to board of directors